Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma

Video

The professor of medicine and pediatrics at Washington University in St. Louis discussed updated survival data from SPEARHEAD-1.

"SPEARHEAD is one of the most interesting things I've had the privilege of working on in my career for synovial sarcoma patients that are not only HLA*02, but also express the MAGE-A4 antigen. The ability to take patients’ T-cells out of their body, remanufacture them and put them back, has led to a T spear therapy for synovial sarcoma that has deep and durable responses. In fact, it's just been made public that they're now going for a traditional approval and no longer an accelerated approval, because the data is that strong.”

Patients with advanced synovial sarcoma treated with afamitresgene autoleucel (afami-cel; AdaptImmune) T-cell receptor SPEAR T-cell therapy in the phase 2 SPEARHEAD-1 trial (NCT04044768) have continued to experience a survival benefit. Updated survival data from the trial were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois, by Brian Van Tine, MD, PhD, professor, medicine and pediatrics, Washington University in St. Louis.

CGTLive™’s sister site, OncLive™, spoke with Van Tine to learn more about the updated data survival data, which continues to demonstrate a durable and deep response in treated patients. He noted that AdaptImmune is no longer pursuing an accelerated approval for afami-cel in favor of a traditional approval. He also touched on the manageable safety profile of afami-cel, which includes transient cases of cytokine release syndrome but no new, long-term safety signals. He shared possible next steps for the platform, including targeted other antigens besides MAGE-A4.

Click here for more coverage of ASCO 2023.

REFERENCE
Van Tine BA, Ganjoo KN, Blay JY, et al. The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma. Presented at: ASCO 2023 Annual Meeting; June 2-6; Chicago, Illinois. Poster #497
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
© 2024 MJH Life Sciences

All rights reserved.